Avexa Of Australia Loses CEO In Dust-up Over Canceling HIV Drug
This article was originally published in PharmAsia News
Executive Summary
Australian biotech Avexa canceled development of a promising drug to treat HIV/AIDS because it was unable to reach a deal with potential global partners